Introduction
============

Cancer has major impacts on public health and the economy in both developing and developed countries ([@b1-br-0-0-1048]). In 2012, over 14.1 million new cases of cancer were diagnosed and 8.2 million people succumbed due to cancer worldwide ([@b2-br-0-0-1048]). Certain susceptibility factors, including heavy alcohol intake, tobacco use, high calorific diet and chemical dyes, have been identified as potential susceptibility factors for cancer ([@b3-br-0-0-1048]). An aging population, increased environmental pollution and longer life expectancy, have also contributed to increased incidence rates of cancer ([@b4-br-0-0-1048]). However, the underlying pathogenic mechanisms of cancer remain to be fully elucidated.

Previous studies have indicated that the transition from normal to pre-cancer and cancer cells is a result of a multi-step accumulation of genetic and epigenetic modifications ([@b5-br-0-0-1048],[@b6-br-0-0-1048]). Recent studies have focused on the interaction between heme oxygenase-1 (HO-1) gene polymorphisms and cancer ([@b7-br-0-0-1048],[@b8-br-0-0-1048]). HO-1 is a subtype of HO, which serves an important role as a rate-limiting enzyme in the conversion of heme into biliverdin, CO and Fe^2+^ ([@b9-br-0-0-1048]). HO-1 and its products may regulate the levels of reactive oxygen species (ROS) through anti-apoptotic, anti-oxidation, anti-inflammatory effects, and by mediating autophagy ([@b10-br-0-0-1048]). In turn, ROS may modulate tumorigenesis by causing cell apoptosis/necrosis or an accumulation of DNA damage ([@b11-br-0-0-1048]). Two loci of the HO-1 gene have been focused on when regarding its potential association with cancer, namely the (GT)n repeat length polymorphism \[which according to repeat length is divided into two classes: S (short) and L (long)\] and T(−413)A (rs2071746) ([@b12-br-0-0-1048]--[@b14-br-0-0-1048]); however, results so far are not conclusive. Both loci are localized on chromosome 22q12 and have been identified in the HO-1 gene promoter region ([@b15-br-0-0-1048]).

Although numerous studies on the correlation between these two loci and cancer have been conducted, the results are ambiguous ([@b11-br-0-0-1048]--[@b14-br-0-0-1048],[@b16-br-0-0-1048],[@b17-br-0-0-1048]--[@b29-br-0-0-1048]). Based on previous observations, two previous meta-analyses focused on the association of HO-1 gene polymorphisms with cancer susceptibility ([@b30-br-0-0-1048],[@b31-br-0-0-1048]), though again the data appears inconclusive. Therefore, to clarify the associations between HO-1 gene polymorphisms and cancer susceptibility, an updated meta-analysis was performed in the present study.

Materials and methods
=====================

### Protocol

The current meta-analysis was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines ([@b32-br-0-0-1048]).

### Identification and eligibility of relevant studies

The electronic databases PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), Web of Science (<http://isiknowledge.com>), the Cochrane Library (<http://www.cochranelibrary.com/>), Wanfang Data (<http://www.wanfangdata.com.cn>) and China National Knowledge Infrastructure (<http://www.cnki.net/>) were searched for all studies published before April 10, 2017 that had examined the association between HO-1 gene polymorphisms and cancer. The search strategy was based on combinations of the key words 'heme oxygenase-1 or HMOX1 or HO-1', 'polymorphism or susceptibility' and 'cancer or carcinoma or tumor or malignant or neoplasm'. English or Chinese-language studies were included in the literature search without any special restriction on the source of cases (cancer patients) and controls (normal subjects, free from cancer). Studies in the form of reviews or commentaries and studies in animals or those using cell lines were excluded.

### Inclusion criteria

Included studies met the following criteria: i) Case-control study or cohort study; ii) focus on the association of HO-1 (GT)n and T(−413)A polymorphisms with cancer; iii) provision of an odds ratio (OR) with 95% confidence intervals (CIs) or sufficient data for calculation of OR and 95% CIs.

### Data extraction

The following information were extracted from each eligible study: Name of author, year of publication, ethnicity or geographic location of study subjects, cancer type, study design, genotyping method, cohort age, cohort sex ratio, use of age and sex matching, and consistency of genotype frequencies with Hardy-Weinberg Equilibrium (HWE). Allele and genotype frequencies were extracted or calculated from the published data in the included studies. The bibliographic search and data extraction were carried out by two independent reviewers, and disagreements were resolved by discussion among the reviewers.

### Data synthesis and analysis

The meta-analysis was performed using Review Manager 5.3 (<http://tech.cochrane.org/revman>) and Stata 12.0 software (StataCorp LP, College Station, TX, USA). The χ^2^ test was applied to verify whether the genotype distribution of the control group in each study conformed to HWE. Four genetic models were used: An allele model (L vs. S); a dominant model (LL vs. SS+SL); a co-dominant model (LL vs. SS); and a recessive model (LL+LS vs. SS). To evaluate sources of heterogeneity across studies, subgroup analyses were conducted based on ethnicity, cancer type, tumor location and HWE. Heterogeneity was determined using I^2^ statistics; when I^2^ \<50%, the fixed-effects model was used, while for I^2^ \>50%, the random-effects model was used and meta-regression analysis was performed to detect the source of heterogeneity. Stratification analyses were performed based on the outcome of meta-regression analysis. Results were determined as ORs with 95% CIs and P-values. P\<0.05 was considered to indicate statistical significance. Sensitivity analyses were conducted by omitting each study in turn and by excluding studies with departure from HWE. Funnel plots and Egger\'s/Begg\'s tests were used to visualize the overall effect and to evaluate publication bias, respectively.

Results
=======

### Study characteristics

The systematic literature search identified 206 potentially relevant articles. After excluding duplications, 187 titles and abstracts were screened. A total of 165 articles were excluded due to irrelevance to the aim of the present study. The remaining 22 articles underwent full-text examination, and two studies ([@b33-br-0-0-1048],[@b34-br-0-0-1048]) were excluded due to their analysis of the same subjects reported in two different studies ([@b16-br-0-0-1048],[@b19-br-0-0-1048]), with the latter studies selected due to their inclusion of more data. Another two studies ([@b20-br-0-0-1048],[@b35-br-0-0-1048]) were excluded as genotype data could not be obtained, one study ([@b7-br-0-0-1048]) was not a case-control study, and two studies ([@b8-br-0-0-1048],[@b36-br-0-0-1048]) used cancer patients in the control group. Thus, 14 studies ([@b9-br-0-0-1048],[@b13-br-0-0-1048],[@b15-br-0-0-1048],[@b16-br-0-0-1048],[@b18-br-0-0-1048]--[@b26-br-0-0-1048]) were included in the meta-analysis, among which were 12 studies ([@b9-br-0-0-1048],[@b13-br-0-0-1048],[@b15-br-0-0-1048],[@b16-br-0-0-1048],[@b18-br-0-0-1048]--[@b24-br-0-0-1048]) on (GT)n repeat length polymorphism and three studies ([@b21-br-0-0-1048],[@b25-br-0-0-1048],[@b26-br-0-0-1048]) on T(−413)A single nucleotide polymorphism (SNP) associations with cancer susceptibility ([Table I](#tI-br-0-0-1048){ref-type="table"}).

Meta-analysis
-------------

### HO-1(GT)n repeat length polymorphism and susceptibility to cancer

The association between the HO-1(GT)n repeat length polymorphism and cancer susceptibility was investigated in 12 relevant studies involving 2,471 patients with cancer and 2,654 normal controls. No significant associations were identified between susceptibility to overall cancer and the SNP in any of the four genetic models screened (L vs. S, LL+LS vs. SS, LL vs. SS+SL, LL vs. SS). However, subgroup analyses by ethnicity and cancer type indicated that the HO-1(GT)n repeat length polymorphism was associated with cancer susceptibility in the East Asian, squamous cell carcinoma and digestive tract cancer + East Asian subgroups ([Table II](#tII-br-0-0-1048){ref-type="table"}).

The first subgroup analysis was conducted according to ethnicity. It was identified that the LL and L-allele (LL+LS) genotypes were associated with increased susceptibility to cancer compared with the SS+SL and SS genotypes in the East Asian subgroup (LL+LS vs. SS: OR=1.51, 95% CI=1.11--2.05, P=0.0003; LL vs. SS+SL: OR=1.44, 95% CI=1.04--2.01, P=0.03; LL vs. SS: OR=1.64, 95% CI=1.07--2.52, P=0.02). By contrast, no significant associations were identified in the genetic models with non-East Asian (Caucasian, American, West Asian) populations ([Table II](#tII-br-0-0-1048){ref-type="table"}).

The second subgroup analysis was conducted according to cancer type. It was also identified that patients carrying the LL genotype and L-allele genotypes (LL+LS) had increased susceptibility to squamous cell carcinoma compared with SS+SL and SS genotype carriers (LL+LS vs. SS: OR=1.78, 95% CI=1.35--2.34, P\<0.0001; LL vs. SS+SL: OR=1.71, 95% CI=1.34--2.18, P\<0.0001; LL vs. SS: OR=2.26, 95% CI=1.62--3.14, P\<0.0001). However, no associations were observed in any of the four allelic genetic models with digestive tract cancer ([Table II](#tII-br-0-0-1048){ref-type="table"}).

The third subgroup analysis was conducted according to tumor location and ethnicity. It was observed that patients carrying the LL genotype and L-allele genotypes (LL+LS) had increased susceptibility to digestive tract cancer compared with SL+SS and SS genotype carriers in the East Asian subgroup (LL+LS vs. SS: OR=1.56, 95% CI=1.22--1.98, P=0.003; LL vs. SS: OR=1.80, 95% CI=1.06--3.05, P=0.03). However, no associations were observed in the allelic and co-dominant genetic models regarding cancer susceptibility in the digestive tract cancer + non-East Asian and squamous cell carcinoma + East Asian/non-East Asian subgroups ([Table II](#tII-br-0-0-1048){ref-type="table"}).

Subgroup analysis was also conducted according to HWE. No significant associations were identified between susceptibility to overall cancer and HO-1(GT)n in any of the four genetic models for cases that met or deviated from HWE ([Table II](#tII-br-0-0-1048){ref-type="table"}).

### HO-1 T(−413)A SNP and cancer susceptibility

There were 3 studies that investigated the association between the HO-1 T(−413)A SNP and digestive system neoplasms. The meta-analysis suggested that there were no significant associations between the HO-1 T(−413)A polymorphism and overall cancer susceptibility in any of the genetic models ([Table II](#tII-br-0-0-1048){ref-type="table"}).

### Sensitivity analysis

The stability of the results was assessed by sensitivity analyses, which were conducted for all genetic comparisons by omitting each study in turn. It was determined that no study had substantial influence on the pooled ORs in all genetic models, suggesting the results were stable. In addition, the ORs were unaltered by omitting studies in which the genotype distribution in controls departed from HWE.

### Publication bias

Funnel plots and Begg\'s tests were used to evaluate the publication bias of the included studies. From the funnel plots and Begg\'s tests, no indication of publication bias was identified in the studies on the (GT)n repeat length polymorphism or T(−413)A SNP ([Fig. 1](#f1-br-0-0-1048){ref-type="fig"} and [Table III](#tIII-br-0-0-1048){ref-type="table"}).

Discussion
==========

There are three isoforms of HO in human, namely HO-1, HO-2 and HO-3 ([@b37-br-0-0-1048]). HO-1, also known as heat shock protein 32, is upregulated by a number of chemical and physical stresses ([@b38-br-0-0-1048]). Animal experiments have confirmed that HO-1 localizes to endoplasmic reticulum, caveolae, mitochondria and the nucleus, indicating the possibility that HO-1 serves roles in addition to heme degradation ([@b9-br-0-0-1048]). HO-1 expression is elevated in a variety of tumors and neoplasms ([@b39-br-0-0-1048]). HO-1 and its products may promote tumor growth through anti-apoptotic, anti-oxidation, anti-inflammatory and proliferative effects, and by mediating autophagy ([@b40-br-0-0-1048]--[@b42-br-0-0-1048]). Thus, HO-1 activity is considered to be conducive to tumor growth ([@b43-br-0-0-1048]).

Numerous studies have demonstrated that the LL genotype of the HO-1(GT)n locus may increase cancer susceptibility ([@b12-br-0-0-1048],[@b13-br-0-0-1048],[@b16-br-0-0-1048],[@b18-br-0-0-1048],[@b19-br-0-0-1048],[@b21-br-0-0-1048]). However, the associations identified between the HO-1 polymorphisms and cancer susceptibility are inconsistent, and other studies have come to other conclusions ([@b15-br-0-0-1048],[@b17-br-0-0-1048],[@b26-br-0-0-1048]). Additionally, two previously published meta-analyses reported different conclusions ([@b30-br-0-0-1048],[@b31-br-0-0-1048]). More recently, a number of studies on this topic have been published ([@b19-br-0-0-1048]--[@b25-br-0-0-1048]). Therefore, the present study conducted an update meta-analysis following different inclusion criteria to that used previously to evaluate the association of HO-1 polymorphisms with cancer susceptibility.

The present meta-analysis indicated that there was no significant association between the HO-1(GT)n repeat length polymorphism and overall cancer susceptibility. However, on subgroup analysis, the LL and L-allele (LL+LS) genotypes of the HO-1(GT)n locus were associated with a higher susceptibility to squamous cell carcinoma, digestive tract cancer in East Asian carriers and overall cancer in East Asian carriers compared with the SS and/or SL genotype. By contrast, this association with susceptibility was not observed in any of the four genetic models in non-East Asian (Caucasian, American and West Asian) populations. This may be due to differences in life styles, ethnicity, region, cancer type and tumor location, among other factors. The present study also identified no significant associations between the HO-1 T(−413)A SNP and overall cancer susceptibility. These results are consistent with a previous study by Luo *et al* ([@b31-br-0-0-1048]).

However, the present analysis had a number of limitations, as follows: i) The language was restricted to English and Chinese, which excluded eligible studies in other languages; ii) the sample size of included studies on HO-1 T(−413)A SNP was markedly small; iii) the thresholds defined as class S (short) were not uniform in different studies; iv) to an extent, factors such as differences in age and condition of the patients may have affected the stability of results, though were unavoidable. Collectively, these limitations may have affected the final conclusions.

Nevertheless, the current results indicated that there was no association of the HO-1 (GT)n and T(−413)A polymorphisms with overall cancer susceptibility. However, the L-allele genotypes (LL and LS) may be susceptibility factors for cancer in East Asian, digestive tract cancer in East Asian and squamous cell carcinoma populations. Due to the limitations of the included studies, larger refined studies are now required to confirm these conclusions.

![(A-H) Funnel plots representing the association between (GT)n polymorphism in heme oxygenase-1 (HO-1) gene and cancer susceptibility. (A and E) The allele model (L vs. S; T vs. A); (B and F) the dominant model (LL vs. SS+SL; TT vs. AA+AT); (C and G) the co-dominant model (LL vs. SS; TT vs. AA); (D and H) the recessive model (LL+LS vs. SS; TT+AT vs. AA).](br-08-03-0241-g00){#f1-br-0-0-1048}

###### 

Demographic characteristics of studies included in the meta-analysis of heme oxygenase-1 gene promoter polymorphisms and cancer (2004--2017).

                                                                                                                                            Genotype, SS/SL/LL or AA/AT/TT, n   Frequency of class L or T allele, %   Sex of subjects, total, n (M/F)   years (SD)                                                                         
  ----------------------------------------------------- --------------------------- ------------------------------------ --------- -------- ----------------------------------- ------------------------------------- --------------------------------- ------------ --------------- ---------------- ------------- ------------- -------- ----------------------
  GT(n) repeat length polymorphism                                                                                                                                                                                                                                                                                                         
  Chang, 2004                                           East Asian, Taiwan          Oral squamous cell carcinoma         CC, PCR   ≤25      29/64/54                            17/40/26                              58.5                              55.4         147 (147/0)     83 (83/0)        51.3 (9.8)    47.1 (10.0)   0.82     ([@b16-br-0-0-1048])
  Okamoto, 2006                                         Caucasian, Austria          Melanoma                             CC, PCR   \<25     32/50/70                            46/177/175                            62.5                              66.2         152 (82/70)     398 (206/192)    56.0 (15.0)   48.0 (14.0)   0.90     ([@b17-br-0-0-1048])
  Lo, 2007                                              East Asian, Taiwan          Gastric adenocarcinoma               CC, PCR   ≤25      34/101/48                           47/116/87                             53.8                              58.0         183 (130/53)    250 (176/74)     67.5 (12.8)   51.1 (16.6)   0.22     ([@b18-br-0-0-1048])
  Hong, 2007                                            American, USA               Postmenopausal breast cancer         CC, PCR   ≤25      52/183/243                          47/217/228                            70.0                              68.4         505 (0/505)     502 (0/502)      N/A           N/A           0.65     ([@b19-br-0-0-1048])
  Hu, 2010                                              East Asian, China           Esophageal squamous cell carcinoma   CC, PCR   \<25     29/69/45                            90/117/57                             55.6                              43.8         143 (N/A)       264 (N/A)        61.3 (10.4)   58.1 (10.0)   0.11     ([@b21-br-0-0-1048])
  Jirásková, 2012                                       Caucasian, Republic Czech   Sporadic colorectal cancer           CC, PCR     \<27   100/386/291                         133/454/399                           62.3                              63.5         777 (453/324)   986 (571/415)    61.8 (11.0)   49.2 (11.0)   0.83     ([@b29-br-0-0-1048])
  Murakami, 2012                                        East Asian, Japan           Malignant mesothelioma               CC, PCR   \<24       2/29/47                           6/19/19                               78.8                              64.8         78 (58/20)      44 (33/11)       64.8 (8.5)    66.7 (9.0)    0.72     ([@b12-br-0-0-1048])
  Wang, 2014                                            East Asian, China           Esophageal squamous cell carcinoma   CC, PCR   ≤25      1/51/41                             2/63/33                               71.5                              86.2         93 (48/45)      98 (51/47)       61.0 (8.0)    58.0 (8.0)    0.01     ([@b22-br-0-0-1048])
  Hsu, 2015                                             East Asian, Taiwan          Skin cancers                         CC, PCR   ≤28      17/34/14                            47/111/41                             52.3                              51.5         65 (N/A)        199 (N/A)        56.1 (6.9)    54.4 (6.3)    0.10     ([@b25-br-0-0-1048])
  Hu, 2015                                              East Asian, China           Esophageal squamous cell carcinoma   CC, PCR   \<25     34/50/42                            57/46/31                              53.2                              40.3         126 (83/43)     134 (77/57)      61.0 (8.0)    57.0 (10.0)   0.01     ([@b23-br-0-0-1048])
  Motovali-Bashi, 2015                                  West Asian, Iran            Gastric cancer                       CC, PCR   ≤28      31/18/11                            22/21/57                              33.3                              67.5         60 (40/20)      100 (60/40)      60.1 (10.9)   54.1 (12.0)   \<0.01   ([@b26-br-0-0-1048])
  Tang, 2015                                            East Asian, China           Laryngeal squamous cell carcinoma    CC, PCR     \<25   24/71/47                            27/57/14                              58.1                              43.4         142 (140/2)     98 (97/1)        61.5 (9.6)    68.3 (11.9)   0.07     ([@b27-br-0-0-1048])
  T(−413)A (rs2071746) single-nucleotide polymorphism                                                                                                                                                                                                                                                                                      
  Song, 2015                                            East Asian, China           Hepatocellular carcinoma             CC, PCR   N/A      62/136/69                           43/131/75                             51.3                              56.4         267 (237/30)    249 (135/114)    49.4 (11.1)   46.6 (7.0)    0.27     ([@b28-br-0-0-1048])
  Andersen, 2015                                        Caucasian, Denmark          Colorectal cancer                    CS, PCR   N/A      310/446/172                         587/864/275                           42.6                              41.0         928 (521/407)   1726 (922/804)   57.8 (3.3)    56.5 (3.5)    0.15     ([@b24-br-0-0-1048])
  Jirásková, 2012                                       Caucasian, Republic Czech   Sporadic colorectal cancer           CC, PCR     \<27   253/372/152                         311/497/177                           43.5                              43.2         777 (453/324)   986 (571/415)    61.8 (11.0)   49.2 (11.0)   0.39     ([@b29-br-0-0-1048])

CC, case-control; CS, case-cohort study; PCR, polymerase chain reaction; M, man; F, female; HWE, Hardy-Weinberg equilibrium; N/A, not available.

###### 

Results from the meta-analysis of the association between cancer susceptibility and heme oxygenase-1 gene promoter polymorphisms.

                                                                                                       Genetic model                                                                                                                                                                                      
  ------------------------------------------------------- -------------------- ----------------------- ------------------ ------------------ ------------------ ------------------ ---------------- -------------- ------------------ ---------------- -------------- ------------------ ---------------- --------------
  (GT)n polymorphism with cancer                                                                                                                                                                                                                                                                          
    Total                                                 12                   2,444/3,146             1.00 (0.79,1.27)   0.99               87                 1.08 (0.77,1.51)   0.67             76             1.14 (0.87,1.51)   0.34             79             1.16 (0.76,1.79)   0.49             81
    East Asian                                              8                  977/1,170               1.19 (0.87,1.64)   0.27               82                 1.51 (1.11,2.05)   0.0003           38             1.44 (1.04,2.01)   0.03             64             1.64 (1.07,2.52)   0.02             66
    Non-East Asian                                          4                  1,467/1,976             0.73 (0.50,1.07)   0.10               91                 0.63 (0.37,1.07)   0.08             83             0.77 (0.49,1.22)   0.27             87             0.58 (0.31,1.08)   0.09             85
    Meeting HWE                                             9                  2,165/2,814             1.14 (0.96,1.36)   0.14               72                 1.12 (0.82,1.52)   0.49             68             1.21 (0.95,1.54)   0.13             68             1.26 (0.86,1.84)   0.24             73
    Deviating from HWE                                      3                  279/332                 0.55 (0.16,1.93)   0.35               96                 0.91 (0.17,4.75)   0.91             91             0.78 (0.21,2.89)   0.71             92             0.84 (0.09,7.64)   0.83             93
  (GT)n polymorphism with squamous cell carcinoma           5                  651/677                 1.21 (0.79,1.87)   0.38               85                 1.78 (1.35,2.34)   \<0.0001         0              1.71 (1.34,2.18)   \<0.0001         0              2.26 (1.62,3.14)   \<0.0001         4
  (GT)n polymorphism with digestive tract cancer                                                                                                                                                                                                                                                          
    Total                                                   8                  1,671/2,013             0.93 (0.65,1.33)   0.68               91                 1.17 (0.77,1.76)   0.46             77             1.08 (0.71,1.65)   0.72             85             1.20 (0.66,2.19)   0.55             85
    East Asian                                              6                  834/927                 1.14 (0.78,1.67)   0.51               86                 1.56 (1.22,1.98)   0.003            26             1.44 (0.96,2.17)   0.08             72             1.80 (1.06,3.05)   0.03             66
    Non-East Asian                                          2                  837/1086                0.49 (0.13,1.87)   0.30               97                 0.55 (0.14,2.13)   0.39             92             0.40 (0.08,2.03)   0.27             94             0.38 (0.06,2.59)   0.32             95
                                                                                                                                                                                                                                                                                                          
                                                                                                       **T vs. A**        **TT+TA vs. AA**   **TT vs. AA+TA**   **TT vs. AA**                                                                                                                             
                                                                                                                                                                                                                                                                                                          
                                                          **No. of studies**   **Cases/controls, n**   **OR (95% CI)**    **P~1~-value**     **I^2^ (%)**       **OR (95% CI)**    **P~1~-value**   **I^2^ (%)**   **OR (95% CI)**    **P~1~-value**   **I^2^ (%)**   **OR (95% CI)**    **P~1~-value**   **I^2^ (%)**
                                                                                                                                                                                                                                                                                                          
  T(−413)A polymorphism with digestive system neoplasms                                                                                                                                                                                                                                                   
    Total                                                   3                  1,972/2,961             1.02 (0.94,1.10)   0.70               48                 0.97 (0.86,1.10)   0.61             29             1.10 (0.95,1.27)   0.20             36             1.00 (0.76,1.33)   0.98             57

P~1~-values were obtained from Z tests for random or fixed-effects models.

###### 

Eggers and Beggs test results.

  Association                                            Genetic model   P~1~-value   P~2~-value
  ------------------------------------------------------ --------------- ------------ ------------
  (GT)n polymorphism and cancer                          L vs. S         0.072        0.732
                                                         LL+LS vs. SS    0.023        0.244
                                                         LL vs. SS+SL    0.744        0.631
                                                         LL vs. SS       0.397        0.945
  (GT)n polymorphism and squamous cell carcinoma         L vs. S         0.673        0.806
                                                         LL+LS vs. SS    0.653        0.806
                                                         LL vs. SS+SL    0.917        0.806
                                                         LL vs. SS       0.691        1.000
  (GT)n polymorphism and digestive tract cancer          L vs. S         0.107        1.000
                                                         LL+LS vs. SS    0.024        0.386
                                                         LL vs. SS+SL    0.543        0.174
                                                         LL vs. SS       0.300        0.902
  T(−413)A polymorphism and digestive system neoplasms   T vs. A         0.491        1.000
                                                         TT+TA vs. AA    0.157        1.000
                                                         TT vs. AA+TA    0.675        1.000
                                                         TT vs. AA       0.285        0.296

P~1~-value, Eggers test result; P~2~-value, Beggs test result.
